[{"address1": "Building A", "address2": "Fosun Technology Park No. 1289 Yishan Road", "city": "Shanghai", "zip": "200233", "country": "China", "phone": "86 21 3398 7000", "fax": "86 21 3398 7020", "website": "https://www.fosunpharma.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company's product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III. It also engages in the import and export of medical equipment; provision of related and other consulting services; medical devices and diagnosis products, and healthcare service; and investment management, as well as involves in the retail and wholesale distribution of medicines. The company was founded in 1994 and is based in Shanghai, China.", "fullTimeEmployees": 39309, "companyOfficers": [{"maxAge": 1, "name": "Mr. Kexin  Wang", "age": 58, "title": "Executive Co-Chairman", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 2139621, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yifang  Wu", "age": 54, "title": "Executive Chairman", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1703837, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Deyong  Wen", "age": 52, "title": "Joint President,CEO & Executive Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1403069, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiaohui  Guan", "age": 52, "title": "Executive Vice Chairman", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1282228, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shengli  Li", "age": 49, "title": "Executive President & Chief Growth Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rongli  Feng", "age": 48, "title": "Executive President, Chief Human Resources Officer & GM of Human Resources Department", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jing  Li", "age": 51, "title": "Executive President and CEO of Established Medicines Manufacturing & Supply Division", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wang  Xingli M.D., Ph.D.", "age": 61, "title": "Executive President, Co-CEO of Innovative Medicines Division and CEO of Global R&D Center", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wenjie  Zhang", "age": 56, "title": "Executive President & Co-CEO of Innovative Drug Division", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiaolei  Wu", "age": 43, "title": "VP & CFO", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 3, "compensationRisk": 3, "shareHolderRightsRisk": 10, "overallRisk": 3, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.59, "open": 1.59, "dayLow": 1.59, "dayHigh": 1.65, "regularMarketPreviousClose": 1.59, "regularMarketOpen": 1.59, "regularMarketDayLow": 1.59, "regularMarketDayHigh": 1.65, "dividendRate": 0.04, "dividendYield": 0.0241, "exDividendDate": 1721952000, "payoutRatio": 0.6172, "fiveYearAvgDividendYield": 2.03, "beta": 0.648, "trailingPE": 15.95, "volume": 100000, "regularMarketVolume": 100000, "averageVolume": 2182, "averageVolume10days": 210, "averageDailyVolume10Day": 210, "bid": 1.41, "ask": 1.74, "bidSize": 40000, "askSize": 40000, "marketCap": 7568482304, "fiftyTwoWeekLow": 1.515, "fiftyTwoWeekHigh": 2.435, "priceToSalesTrailing12Months": 0.18702775, "fiftyDayAverage": 1.63692, "twoHundredDayAverage": 1.769395, "trailingAnnualDividendRate": 0.27, "trailingAnnualDividendYield": 0.16981132, "currency": "USD", "enterpriseValue": 34711105536, "profitMargins": 0.04531, "floatShares": 1698958804, "sharesOutstanding": 551939968, "heldPercentInsiders": 0.14222, "heldPercentInstitutions": 0.17424, "bookValue": 17.585, "priceToBook": 0.09070231, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.222, "netIncomeToCommon": 1834643072, "trailingEps": 0.1, "enterpriseToRevenue": 0.858, "enterpriseToEbitda": 10.067, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "SFOSF", "underlyingSymbol": "SFOSF", "shortName": "SHANGHAI FOSUN PHARMACEUTICAL G", "longName": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd.", "firstTradeDateEpochUtc": 1398087000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c6c322b7-2fc6-3dce-b9ec-fb98a16f1f49", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.595, "recommendationKey": "none", "totalCash": 16101010432, "totalCashPerShare": 6.028, "ebitda": 3447848192, "totalDebt": 34657222656, "quickRatio": 0.685, "currentRatio": 0.93, "totalRevenue": 40467161088, "debtToEquity": 58.879, "revenuePerShare": 15.15, "returnOnAssets": 0.00778, "returnOnEquity": 0.04198, "freeCashflow": -1622016384, "operatingCashflow": 3511212800, "earningsGrowth": -0.227, "revenueGrowth": -0.021, "grossMargins": 0.46922, "ebitdaMargins": 0.085200004, "operatingMargins": 0.067150004, "financialCurrency": "CNY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]